KI has received per diem, including speaking fees, from Janssen Pharmaceutical and Ono Pharmaceutical and has received research funding from AstraZeneca, AbbVie, Incyte Biosciences Japan, Bristol Myers Squibb, Eisai, Novartis Pharma, Janssen Pharmaceutical, Yakult Honsha, Daiichi Sankyo, Chugai Pharmaceutical, BeiGene, Genmab, Loxo Oncology, Otsuka Pharmaceutical, and Regeneron Pharmaceuticals. NF has received per diem, including speaking fees, from Bristol Myers Squibb, SymBio Pharmaceuticals, Chugai Pharmaceutical, and HUYA Bioscience International and has received research funding from AbbVie, Incyte Biosciences Japan, Kyowa Kirin, Chordia Therapeutics, Genmab, Celgene, Takeda Pharmaceuticals, Chugai Pharmaceutical, Bayer Yakuhin, and Loxo Oncology.